FOCUSED INVESTIGATOR TRAINING PROGRAM FACULTY

University of Arizona College of Pharmacy
JUNE 11–16, 2011

This career development program, established by the ACCP Research Institute in 2007, annually provides up to 25 experienced investigators with the knowledge and skills needed to become independent clinical, translational, or health services researchers. The target audience is pharmacist investigators with prior pilot research data who want to create a focused, competitive grant proposal that will support a significant extramural grant.

Through this mentored program, each experienced investigator takes necessary steps toward preparing a K, R01, or similar investigator-initiated application for submission to the National Institutes of Health (NIH) or other major funding source.

The faculty is engaged in a close mentoring relationship with the investigators. Faculty mentors are funded, experienced researchers and educators. A mixture of highly skilled clinical, basic science, and biostatical faculty researchers are on-site to meet the diverse needs of the investigator participants.

Julie M. Banderas, Pharm.D., FCCP, BCPS, is a professor of medicine and a professor in the Department of Biomedical and Health Informatics at the University of Missouri–Kansas City (UMKC) School of Medicine. She is the assistant dean for graduate studies for the UMKC School of Medicine and teaches a series of Responsible Conduct of Research courses for UMKC graduate programs. Her clinical research has primarily focused on HIV/AIDS in the areas of transmission prevention and treatment adherence. Dr. Banderas is a member of the ACCP Board of Regents.

Barry L. Carter, Pharm.D., FCCP, is professor in the Division of Clinical and Administrative Pharmacy and a professor of family medicine. He is a Fellow of the American Heart Association (FAHA) Council on High Blood Pressure Research, a Fellow of ACCP (FCCP), and a board-certified pharmacotherapy specialist (BCPS). He has served as president of ACCP, and he is a member of the National Heart, Lung, and Blood Institute's National High Blood Pressure Education Program Committee. His current grant awards include two R01s from the National Heart, Lung, and Blood Institute to evaluate physician/pharmacist collaborative models to improve blood pressure control and adherence to hypertension guidelines.

John D. Cleary, Pharm.D., FCCP, joined the University of Mississippi School of Pharmacy in 1986. He is a professor and vice chair of research in the Pharmacy Practice Department and antimycotic program director for the Mycotic Research Center. He has published more than 120 peer-reviewed manuscripts and book chapters in the area of infectious diseases, many of which focus on improving antifungal pharmacotherapy. He has received an R01 in antifungal pharmacogenomics, STTR (Small Business Technology Transfer), and SBIR (Small Business Innovation Research) in addition to several other fundings. In recognition of his contributions to the profession, he has received many awards, among the most prestigious of which is a Fulbright scholarship. Dr. Cleary has been part of the College since 1985 and has served ACCP as a member of the Infectious Diseases PRN and Publications Committee as well as the Board of Trustees for the Research Institute.

Vicki L. Ellingrod, Pharm.D., FCCP, BCPP, is an associate professor of clinical, social, and administrative sciences in the College of Pharmacy, the Department of Psychiatry in the School of Medicine, and director of the Clinical Pharmacogenomics Laboratory at the University of Michigan. She received her bachelor's of science degree in pharmacy from the University of Minnesota in 1992 and, in 1994, her Pharm.D. degree. From 1994 to 1996, she completed a postdoctoral fellowship in psychopharmacology/pharmacogenetics at the University of Iowa and then joined the faculty in 1996 as an assistant professor. There, she completed a K08 training grant funded by the NIMH (National Institute of Mental Health). In 2006, she joined the faculty at the University of Michigan. Her research focuses on the pharmacogenomics of mental health treatment.

Susan C. Fagan, Pharm.D., FCCP, BCPS, has been a professor of pharmacy at the University of Georgia (UGA) and an adjunct professor of neurology at the Medical College of Georgia (MCG) in Augusta, Georgia, since 1999. In 2007, she became associate department head and assistant dean for the UGA pharmacy program at MCG, and in August 2008, she was appointed Albert W. Jowdy Professor of Pharmacy Care. She is a member of the program in Clinical and Experimental Therapeutics at UGA and the Charlie Norwood VA Medical Center. Dr. Fagan is an active member of the Clinical Trials study section of the NIH/National Institute of Neurological Disorders and Stroke (NIH-NINDS); her research in stroke is funded by NIH-NINDS and the VA Merit Review.

Reginald F. Frye, Pharm.D., FCCP, is an associate professor in the Department of Pharmacy Practice at the University of Florida College of Pharmacy. Before holding his current position, he was on the faculty at the University of Pittsburgh School of Pharmacy. His research focuses on the identification and characterization of genetic and nongenetic factors (e.g., drug interactions, age, disease) that contribute to variability in drug metabolism. He has published more than 80 peer-reviewed research publications and several book chapters. Dr. Frye is an editorial board member for journals including Pharmacotherapy and has been a reviewer on NIH study sections. The pharmaceutical industry, private foundations, and the NIH have funded his research.

Mary M. Gerkovich, Ph.D., is research associate professor, Department of Biomedical and Health Informatics, School of Medicine, at UMKC. Dr. Gerkovich specializes in research design and methodology, data management, and statistical analysis. She has more than 30 years' experience conducting research on a variety of human health–related projects, and she has been a coinvestigator on several projects for both government and industrial clients, which have provided more than $5 million in research funding. Most recently, she was involved in research testing of behavioral interventions designed to improve patients' adherence to their medication regimens as well as research using large administrative claims data sets to test the relative effectiveness of conventional and alternative treatments of musculoskeletal conditions. She currently splits her time between research activities and teaching in the department's graduate program. Dr. Gerkovich has cowritten more than 40 peer-reviewed journal articles and more than 10 book chapters, and she has served as a reviewer on an NIH study section.

Gene D. Morse, Pharm.D., FCCP, BCPS, is professor and associate director of the New York State Center of Excellence in Bioinformatics and Life Sciences at the University at Buffalo (UB). Dr. Morse has been actively involved in HIV clinical pharmacology research since the introduction of antiretrovirals in 1986. Dr. Morse has NIAID (National Institute of Allergy and Infectious Diseases) support through the UB ACTG (AIDS Clinical Trials Group) Pharmacology Specialty Laboratory and a contract for the HIV Clinical Pharmacology Quality Assurance Program. These programs integrate with the Fogarty International Center AIDS International Training and Research Program, which Dr. Morse directs with the University of Zimbabwe. Dr. Morse directs the UB HIV Clinical Pharmacology Laboratory, which has gained an international reputation for its work in bioanalysis, pharmacokinetics, and pharmacogenomics. In addition, Dr. Morse is director of the Medication Management Research Network, a federally certified patient safety organization. On a regional basis, he is a member of the New York Patient Advisory and Safety Enhancement Committee and chairs its technology subcommittee. Dr. Morse contributes to the Health Information Technology Program within the UB Academic Health Center, and he recently became associate director of the UB Institute for Healthcare Informatics. Dr. Morse has 25 years of NIH funding with extensive experience in clinical and translational research.

Mary H.H. Ensom (formerly Chandler), Pharm.D., FCCP, is a professor of pharmaceutical sciences; a recipient of the Distinguished University Scholar Award, University of British Columbia (UBC); and a clinical pharmacy specialist, Children's & Women's Health Centre of British Columbia. From 1987 to 1997, she was on the faculty at the University of Kentucky College of Pharmacy. Her research program focuses on clinical pharmacokinetics/dynamics/genetics and is funded by CIHR/NSERC (Canada's major granting councils), foundations, and industry. She has written or cowritten more than 400 publications (including about 170 articles in peer-reviewed journals). In 2006, she received the ACCP Russell R. Miller Publication Award and, in 2007, the UBC Killam Research Prize in Science. Dr. Ensom is editor for the Canadian Journal of Hospital Pharmacy (and is on the editorial boards of five other international journals) and is a fellow of the Canadian Academy of Health Sciences, Canada's equivalent to the Institute of Medicine.

Gregory Stoddard, Ph.D., MBA, MHP, is a biostatistician with 30 years' experience in medical and pharmacy practice research. For 10 years, he worked at Becton, Dickinson and Company as the project manager of a clinical trials program. Previously a clinical assistant professor of pharmacy practice, he is now an adjunct assistant professor of orthopedics at the University of Utah School of Medicine. He is also the codirector of the Study Design and Biostatistics Center at the university, which is the biostatistics core supported by an NIH Clinical and Translational Science Award (CTSA). For the past 10 years, he has taught courses in biostatistics and epidemiology at the University of Utah School of Medicine. He has cowritten 70 articles published in medical or pharmacy journals. He has written a biostatistics textbook that is freely available as a full-text electronic book at http://www.ccts.utah.edu/biostats/?pageId=5385. Most notably, Dr. Stoddard has written the Statistical Methods and Sample Size sections for more than 30 NIH grant applications, with a very high success rate of funding.

Lynda Welage, Pharm.D., FCCP, is professor of clinical, social, and administrative sciences and associate dean for academic affairs at the University of Michigan College of Pharmacy. In addition, she is associate director for the Education, Career Development, and Mentoring programs at the Michigan Institute for Clinical Health Research as part of the NIH CTSA. Her current research efforts focus on evaluating alterations in intestinal transport processes during acute inflammatory states. Dr. Welage has published more than 89 peer-reviewed articles and book chapters in the areas of critical care and the pharmacotherapeutics of gastrointestinal diseases.

Gary C. Yee, Pharm.D., FCCP, BCOP, is professor and associate dean for Academic Affairs, College of Pharmacy, University of Nebraska Medical Center, in Omaha. He completed his bachelor's of science degree in pharmacy at the University of Washington, his Pharm.D. degree at the Philadelphia College of Pharmacy and Science, and his postdoctoral training at St. Jude Children's Research Hospital. Before accepting his current position, he held positions at the Fred Hutchinson Cancer Research Center and the University of Florida. He has been involved in oncology practice, education, and research for more than 25 years. In addition, he has published more than 100 research articles, reviews, and book chapters, and his research findings have been published in several prominent journals, including The New England Journal of Medicine and The Lancet.

Apply online at: *http://www.accpri.org/fit/* • Online applications close on April 1, 2011